罗索那班
外观
临床资料 | |
---|---|
ATC码 |
|
识别信息 | |
| |
CAS号 | 861151-12-4 |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C21H21Cl3N4O |
摩尔质量 | 451.78 g·mol−1 |
3D模型(JSmol) | |
| |
|
罗索那班(INN:Rosonabant,开发代号:E-6776)或译作罗索纳班,是一种用作CB1受体拮抗剂/反向激动剂的药物,埃斯特夫正在研究将其作为治疗肥胖症的食欲抑制剂。[1][2]在相关的CB1拮抗剂利莫那班于2008年11月停用后不久,临床用药的开发明显停止,原因是有报道称其及其它类似药剂会引起严重的精神不良反应,例如焦虑、抑郁和自杀意念。[3][4][5]
参见
[编辑]参考资料
[编辑]- ^ Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs. March 2009, 14 (1): 43–65. PMID 19249987. S2CID 74250986. doi:10.1517/14728210902736568.
- ^ Tim C. Kirkham; S. J. Cooper. Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. 2007: 325 [12 May 2012]. ISBN 978-0-12-370633-1.
- ^ Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology. December 2009, 68 (6): 861–74. PMC 2810797 . PMID 20002080. doi:10.1111/j.1365-2125.2009.03549.x.
- ^ Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current Topics in Medicinal Chemistry. 2009, 9 (6): 482–503. PMID 19689362. doi:10.2174/156802609788897844. (原始内容存档于2013-05-22).
- ^ Moreira, Fabrício A.; Crippa, José Alexandre S. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria. June 2009, 31 (2): 145–153. ISSN 1516-4446. PMID 19578688. doi:10.1590/S1516-44462009000200012 .